⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 23, 2026HaematologicaOpen Access

Relapse risk and survival benchmarks for non-transplanted acute myeloid leukemia patients in first complete remission

Eitan Kugler Farhad Ravandi Alex Bazinet Courtney D. Dinardo Naval Daver Musa Yilmaz Short Nm Wei Ying Jen Jayastu Senapati Abhishek Maiti Gautam Borthakur Guillermo Garcia-Manero H Kantarjian Tapan M. Kadia

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to define survival outcomes and relapse risks for acute myeloid leukemia (AML) patients in complete remission without transplantation.
Retrospective analysis of 362 adults with de novo AML achieving complete remission between 2016-2023.
Exclusion of patients with acute promyelocytic leukemia (APL) and corebinding factor AML.
Cohort stratification into low-intensity therapy (257 patients) and intensive therapy (105 patients).
Median relapse-free survival was 11 months and overall survival was 19 months.
Venetoclax usage led to a significant reduction in 24-month relapse rates: from 68% to 45% in low-intensity therapy and from 49% to 27% in intensive therapy (p<0.05).

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Retrospective analysis evaluates relapse and survival benchmarks in AML patients post-remission, indicating importance for treatment strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kugler et al. (2026) studied this question.

synapsesocial.com/papers/6a65a61ad3aea3239cd77b27 https://doi.org/10.3324/haematol.2026.300935

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation2025
2Results of treating relapsed and refractory acute myeloid leukemia at a reference center in Latin America: the importance of outpatient hematopoietic stem cell transplantation2024 · 1 citations
3Outcomes and genetic dynamics of acute myeloid leukemia at first relapse2024 · 15 citations
4Allogeneic Transplantation Versus Chemotherapy as Postremission Therapy for Acute Myeloid Leukemia: A Prospective Matched Pairs AnalysisCohort Study · 2013 · 106 citations
5Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemiaPrognostic Study · 2020 · 63 citations

Retrospective, single-center analysis of second allogeneic stem cell transplantation versus non-transplant regimens for acute myeloid leukemia patients with relapse after first transplantation2026
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study2024
Low-Intensity Pretransplant Therapy in Acute Myeloid Leukemia: A 13-Year Single-Center Experience2025
BCL6 in B-cell lymphomas: old target, new tricks?Haematologica · 2026
Platelet transfusion biology: from hemostatic support to inflammatory and immune signalingHaematologica · 2026

More from Haematologica

More from The University of Texas MD Anderson Cancer Center